Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma
The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma. The protocol, consisting of 300 mg/day of thalidomide administered orally, intravenous incadronate (10 mg/day) administered wee...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2005-10, Vol.82 (3), p.243-247 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 247 |
|---|---|
| container_issue | 3 |
| container_start_page | 243 |
| container_title | International journal of hematology |
| container_volume | 82 |
| creator | OCHIAI, Naoya YAMADA, Noriko UCHIDA, Ryo FUCHIDA, Shin-Ichi OKANO, Akira HATSUSE, Mayumi OKAMOTO, Masashi ASHIHARA, Eishi SHIMAZAKI, Chihiro |
| description | The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma. The protocol, consisting of 300 mg/day of thalidomide administered orally, intravenous incadronate (10 mg/day) administered weekly, and 12 mg/day dexamethasone for 4 days, was repeated every 3 weeks. Evaluations of efficacy and toxicity were carried out every 3 weeks and were continued for 3 cycles. Three patients were excluded during the study because of apnea, severe somnolence, and pancytopenia. Of 9 evaluated patients, the partial responses achieved in 3 patients and the minor responses achieved in 4 patients corresponded to a response rate of 78% according to the criteria of the European Group for Blood and Marrow Transplantation. In addition, painful osteolytic symptoms improved rapidly after 1 cycle of TID therapy in the 10 patients evaluated. These data suggest that TID is a feasible and promising therapeutic approach for refractory and relapsed multiple myeloma. |
| doi_str_mv | 10.1532/IJH97.05049 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1891885061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1891885061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-a0a5f069f7ecbbbd4373ffee6c23e8cf9ad0213212835d39b95449414b3e076c3</originalsourceid><addsrcrecordid>eNpd0U1rFTEUBuAgir2trtxLEISCTs3nJFnKRW2l4EbXQyY5Q1OSyZjMUO-_N95eKLhKDjwckvdF6A0lV1Ry9unm-7VRV0QSYZ6hHdW97LhS4jnaEcNkJxUlZ-i81ntCqCJCvURntGdESaN3aNnnNIbZriHPeL2DYpcDfgjrXRtsDD6n4OEjDrOzvuTm2mBnjz38sQmaqXkGPOWCC0S7VPD4eJ-KdWsuB5y2uIYlAk4HiDnZV-jFZGOF16fzAv36-uXn_rq7_fHtZv_5tnOC9WtniZUT6c2kwI3j6AVXfJoAesc4aDcZ6wmjnFGmufTcjEYKYQQVIweiescv0OXj3qXk3xvUdUihOojRzpC3OlBtqNaS9LTRd__R-7yVub1uYFTxFqjmDX14RK7kWtsHh6WEZMthoGT418Nw7GE49tD029PKbUzgn-wp-Aben4CtzsYW1-xCfXKKk8Y0_wsWBZD7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217386583</pqid></control><display><type>article</type><title>Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>OCHIAI, Naoya ; YAMADA, Noriko ; UCHIDA, Ryo ; FUCHIDA, Shin-Ichi ; OKANO, Akira ; HATSUSE, Mayumi ; OKAMOTO, Masashi ; ASHIHARA, Eishi ; SHIMAZAKI, Chihiro</creator><creatorcontrib>OCHIAI, Naoya ; YAMADA, Noriko ; UCHIDA, Ryo ; FUCHIDA, Shin-Ichi ; OKANO, Akira ; HATSUSE, Mayumi ; OKAMOTO, Masashi ; ASHIHARA, Eishi ; SHIMAZAKI, Chihiro</creatorcontrib><description>The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma. The protocol, consisting of 300 mg/day of thalidomide administered orally, intravenous incadronate (10 mg/day) administered weekly, and 12 mg/day dexamethasone for 4 days, was repeated every 3 weeks. Evaluations of efficacy and toxicity were carried out every 3 weeks and were continued for 3 cycles. Three patients were excluded during the study because of apnea, severe somnolence, and pancytopenia. Of 9 evaluated patients, the partial responses achieved in 3 patients and the minor responses achieved in 4 patients corresponded to a response rate of 78% according to the criteria of the European Group for Blood and Marrow Transplantation. In addition, painful osteolytic symptoms improved rapidly after 1 cycle of TID therapy in the 10 patients evaluated. These data suggest that TID is a feasible and promising therapeutic approach for refractory and relapsed multiple myeloma.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1532/IJH97.05049</identifier><identifier>PMID: 16207598</identifier><language>eng</language><publisher>Tokyo: Springer</publisher><subject><![CDATA[Aged ; Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - adverse effects ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biological and medical sciences ; Bone Density Conservation Agents - administration & dosage ; Bone Density Conservation Agents - adverse effects ; Dexamethasone - administration & dosage ; Dexamethasone - adverse effects ; Diphosphonates - administration & dosage ; Diphosphonates - adverse effects ; Disease-Free Survival ; Female ; Hematologic and hematopoietic diseases ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Multiple Myeloma - complications ; Multiple Myeloma - drug therapy ; Multiple Myeloma - mortality ; Osteolysis - etiology ; Osteolysis - mortality ; Recurrence ; Thalidomide - administration & dosage]]></subject><ispartof>International journal of hematology, 2005-10, Vol.82 (3), p.243-247</ispartof><rights>2006 INIST-CNRS</rights><rights>The Japanese Society of Hematology 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-a0a5f069f7ecbbbd4373ffee6c23e8cf9ad0213212835d39b95449414b3e076c3</citedby><cites>FETCH-LOGICAL-c426t-a0a5f069f7ecbbbd4373ffee6c23e8cf9ad0213212835d39b95449414b3e076c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17305988$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16207598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OCHIAI, Naoya</creatorcontrib><creatorcontrib>YAMADA, Noriko</creatorcontrib><creatorcontrib>UCHIDA, Ryo</creatorcontrib><creatorcontrib>FUCHIDA, Shin-Ichi</creatorcontrib><creatorcontrib>OKANO, Akira</creatorcontrib><creatorcontrib>HATSUSE, Mayumi</creatorcontrib><creatorcontrib>OKAMOTO, Masashi</creatorcontrib><creatorcontrib>ASHIHARA, Eishi</creatorcontrib><creatorcontrib>SHIMAZAKI, Chihiro</creatorcontrib><title>Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><description>The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma. The protocol, consisting of 300 mg/day of thalidomide administered orally, intravenous incadronate (10 mg/day) administered weekly, and 12 mg/day dexamethasone for 4 days, was repeated every 3 weeks. Evaluations of efficacy and toxicity were carried out every 3 weeks and were continued for 3 cycles. Three patients were excluded during the study because of apnea, severe somnolence, and pancytopenia. Of 9 evaluated patients, the partial responses achieved in 3 patients and the minor responses achieved in 4 patients corresponded to a response rate of 78% according to the criteria of the European Group for Blood and Marrow Transplantation. In addition, painful osteolytic symptoms improved rapidly after 1 cycle of TID therapy in the 10 patients evaluated. These data suggest that TID is a feasible and promising therapeutic approach for refractory and relapsed multiple myeloma.</description><subject>Aged</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Bone Density Conservation Agents - administration & dosage</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Dexamethasone - administration & dosage</subject><subject>Dexamethasone - adverse effects</subject><subject>Diphosphonates - administration & dosage</subject><subject>Diphosphonates - adverse effects</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Myeloma - complications</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - mortality</subject><subject>Osteolysis - etiology</subject><subject>Osteolysis - mortality</subject><subject>Recurrence</subject><subject>Thalidomide - administration & dosage</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpd0U1rFTEUBuAgir2trtxLEISCTs3nJFnKRW2l4EbXQyY5Q1OSyZjMUO-_N95eKLhKDjwckvdF6A0lV1Ry9unm-7VRV0QSYZ6hHdW97LhS4jnaEcNkJxUlZ-i81ntCqCJCvURntGdESaN3aNnnNIbZriHPeL2DYpcDfgjrXRtsDD6n4OEjDrOzvuTm2mBnjz38sQmaqXkGPOWCC0S7VPD4eJ-KdWsuB5y2uIYlAk4HiDnZV-jFZGOF16fzAv36-uXn_rq7_fHtZv_5tnOC9WtniZUT6c2kwI3j6AVXfJoAesc4aDcZ6wmjnFGmufTcjEYKYQQVIweiescv0OXj3qXk3xvUdUihOojRzpC3OlBtqNaS9LTRd__R-7yVub1uYFTxFqjmDX14RK7kWtsHh6WEZMthoGT418Nw7GE49tD029PKbUzgn-wp-Aben4CtzsYW1-xCfXKKk8Y0_wsWBZD7</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>OCHIAI, Naoya</creator><creator>YAMADA, Noriko</creator><creator>UCHIDA, Ryo</creator><creator>FUCHIDA, Shin-Ichi</creator><creator>OKANO, Akira</creator><creator>HATSUSE, Mayumi</creator><creator>OKAMOTO, Masashi</creator><creator>ASHIHARA, Eishi</creator><creator>SHIMAZAKI, Chihiro</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20051001</creationdate><title>Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma</title><author>OCHIAI, Naoya ; YAMADA, Noriko ; UCHIDA, Ryo ; FUCHIDA, Shin-Ichi ; OKANO, Akira ; HATSUSE, Mayumi ; OKAMOTO, Masashi ; ASHIHARA, Eishi ; SHIMAZAKI, Chihiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-a0a5f069f7ecbbbd4373ffee6c23e8cf9ad0213212835d39b95449414b3e076c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Bone Density Conservation Agents - administration & dosage</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Dexamethasone - administration & dosage</topic><topic>Dexamethasone - adverse effects</topic><topic>Diphosphonates - administration & dosage</topic><topic>Diphosphonates - adverse effects</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Myeloma - complications</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - mortality</topic><topic>Osteolysis - etiology</topic><topic>Osteolysis - mortality</topic><topic>Recurrence</topic><topic>Thalidomide - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OCHIAI, Naoya</creatorcontrib><creatorcontrib>YAMADA, Noriko</creatorcontrib><creatorcontrib>UCHIDA, Ryo</creatorcontrib><creatorcontrib>FUCHIDA, Shin-Ichi</creatorcontrib><creatorcontrib>OKANO, Akira</creatorcontrib><creatorcontrib>HATSUSE, Mayumi</creatorcontrib><creatorcontrib>OKAMOTO, Masashi</creatorcontrib><creatorcontrib>ASHIHARA, Eishi</creatorcontrib><creatorcontrib>SHIMAZAKI, Chihiro</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OCHIAI, Naoya</au><au>YAMADA, Noriko</au><au>UCHIDA, Ryo</au><au>FUCHIDA, Shin-Ichi</au><au>OKANO, Akira</au><au>HATSUSE, Mayumi</au><au>OKAMOTO, Masashi</au><au>ASHIHARA, Eishi</au><au>SHIMAZAKI, Chihiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma</atitle><jtitle>International journal of hematology</jtitle><addtitle>Int J Hematol</addtitle><date>2005-10-01</date><risdate>2005</risdate><volume>82</volume><issue>3</issue><spage>243</spage><epage>247</epage><pages>243-247</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma. The protocol, consisting of 300 mg/day of thalidomide administered orally, intravenous incadronate (10 mg/day) administered weekly, and 12 mg/day dexamethasone for 4 days, was repeated every 3 weeks. Evaluations of efficacy and toxicity were carried out every 3 weeks and were continued for 3 cycles. Three patients were excluded during the study because of apnea, severe somnolence, and pancytopenia. Of 9 evaluated patients, the partial responses achieved in 3 patients and the minor responses achieved in 4 patients corresponded to a response rate of 78% according to the criteria of the European Group for Blood and Marrow Transplantation. In addition, painful osteolytic symptoms improved rapidly after 1 cycle of TID therapy in the 10 patients evaluated. These data suggest that TID is a feasible and promising therapeutic approach for refractory and relapsed multiple myeloma.</abstract><cop>Tokyo</cop><pub>Springer</pub><pmid>16207598</pmid><doi>10.1532/IJH97.05049</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2005-10, Vol.82 (3), p.243-247 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1891885061 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - adverse effects Dexamethasone - administration & dosage Dexamethasone - adverse effects Diphosphonates - administration & dosage Diphosphonates - adverse effects Disease-Free Survival Female Hematologic and hematopoietic diseases Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Multiple Myeloma - complications Multiple Myeloma - drug therapy Multiple Myeloma - mortality Osteolysis - etiology Osteolysis - mortality Recurrence Thalidomide - administration & dosage |
| title | Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A26%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20therapy%20with%20thalidomide,%20incadronate,%20and%20dexamethasone%20for%20relapsed%20or%20refractory%20multiple%20myeloma&rft.jtitle=International%20journal%20of%20hematology&rft.au=OCHIAI,%20Naoya&rft.date=2005-10-01&rft.volume=82&rft.issue=3&rft.spage=243&rft.epage=247&rft.pages=243-247&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1532/IJH97.05049&rft_dat=%3Cproquest_cross%3E1891885061%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217386583&rft_id=info:pmid/16207598&rfr_iscdi=true |